PUBLICATIONS
ページタイトル画像

PUBLICATIONS　/　業　績

[Selected publications] [2025] [2024] [2023] [2022] [2021] [2020] [〜2019]

Selected publications

  • Endo, Y., Hasegawa, I., Igi, A., Onodera, A., Mita, S., Higashi, K., Kurokawa, K., Toyoda, A., Kiuchi, M., Shinzawa, M., Wang, Y., Koyama-Nasu, R., Hirahara, K., Motohashi, S., Nakayama, T., Kimura, M.Y.: SLAMF6 regulates basal T cell receptor signaling and influences invariant natural killer T cell lineage diversity. Int. Immunol. dxaf030 (2025).
  • Koyama-Nasu, R., Wang, Y., Miyano, H., Kimura, M. Y.: Differentiation of Cytotoxic CD8+ T Cell Subsets Under Tumor Progression: Can CD69 Be a New Therapeutic Target? Cancer Science. 0:1–8 (2025).
  • Kobayashi, H., Kimura, M.Y., Hasegawa, I., Suganuma, E., Ikehara, Y., Azuma, K., Ito, T., Ebata, R., Kurashima, Y., Kawasaki, Y., Shiko, Y., Saito, N., Iwase, H., Lee, Y., Noval Rivas, M., Arditi, M., Zuka, M., Hamada, H.*, and Nakayama, T.: Increased Myosin light chain 9 expression during Kawasaki disease vasculitis. Front. Immunol. 13:1036672 (2023).
  • Koyama-Nasu, R., Kimura, M.Y., Kiuchi, M., Aoki, A., Wang, Y., Mita, Y., Hasegawa, I., Endo, Y., Onodera, A., Hirahara, K., Motohashi, S., Nakayama, T.: CD69 imposes tumor-specific CD8+ T cell fate in tumor-draining lymph nodes. Cancer Immunol. Res. 11(8):1085-1099 (2023).
  • Koyama-Nasu, R., Wang, Y., Hasegawa, I., Endo, Y., Nakayama, T. and *Kimura, M. Y.: The cellular and molecular basis of CD69 function in anti-tumor immunity. Int. Immunol. dxac024 (2022). *Corresponding author
  • Yokoyama, M., *Kimura, M.Y., Ito, T., Hayashizaki, K., Endo, Y., Wang, Y., Yagi, R., Nakagawa, T., Kato, N., Matsubara, H. and *Nakayama, T.: Myosin light chain 9/12 regulates the pathogenesis of inflammatory bowel disease. Front. Immunol. 11: 594297 (2021). *Co-corresponding Author
  • Mita, Y., *Kimura, M.Y., Hayashizaki, K., Koyama-Nasu, R., Ito, T., Motohashi, S., Okamoto, Y. and Nakayama, T.: Crucial role of CD69 in anti-tumor immunity through regulating the exhaustion of tumor-infiltrating T cells. Int. Immunol. dxy050 (2018). *Corresponding author, Awarded the “Outstanding Merit Award 2018” by the Editor-in-Chief and Editorial Board of International Immunology.
  • *Kimura, M.Y., Igi, A., Hayashizaki, K., Mita, Y., Shinzawa, M., Kadakia, T., Endo, Y., Ogawa, S., Yagi, R., Motohashi, S., Singer, A., and Nakayama, T.: CD69 prevents PLZFhi innate precursors from prematurely exiting the thymus and aborting NKT2 cell differentiation. Nat. Commun. 9: 3749 (2018). *Corresponding author
  • #Hayashizaki, K., #Kimura, M.Y., #Tokoyoda. K., Hosokawa, H., Shinoda, K., Hirahara, K., Ichikawa, T., Onodera, A., Hanazawa, A., Iwamura, C., Kakuta, J., Muramoto, K., Motohashi, S., Tumes, D.J., Iinuma, T., Yamamoto, H., Ikehara, Y., Okamoto, Y. and *Nakayama, T.: Myosin light chain 9 and 12 are functional ligands for CD69 that regulate airway inflammation. Sci Immunol. 1:eaaf9154 (2016). #Co-first Author
  • *Kimura, M.Y., Thomas, J., Tai, X., Cuinter, T.I., Shinzawa, M., Etzensperger, R., Li, Z., Love, P., Nakayama, T. and *Singer, A.: Timing and duration of MHC I positive selection signals are adjusted in the thymus to prevent lineage errors. Nat. Immunol, 17:1415-23 (2016). *Co-corresponding author
  • Luckey M., Kimura M.Y., Waickman AT., Feigenbaum L., Singer A and *Park JH.: The transcription factor ThPOK suppresses Runx3 and imposes CD4 lineage fate by inducing Suppressors Of Cytokine Signaling, Nat. Immunol, 15(7):638-45 (2014).
  • Kimura, M.Y., Pobezinsky, L.A., Guinter, T.I., Thomas, J., Adams, A., Park, J.H., Tai, X. and *Singer, A.; IL-7 signaling must be intermittent, not continuous, during CD8+ T cell homeostasis to promote cell survival instead of cell death. Nat. Immunol. 14:143-151 (2013).
  • Kimura, M.Y., Iwamura, C., Suzuki, A., Miki, T., Hasegawa, A., Sugaya, K., Yamashita, M., Ishii, S. and *Nakayama, T.: Schnurri-2 controls memory Th1 and Th2 cell numbers in vivo. J. Immunol. 178:4926-4936 (2007).
  • Iwamura, C., Kimura, M.Y., Shinoda, K., Endo, Y., Hasegawa, A., Yamashita, M. and *Nakayama, T.: Schnurri-2 regulates Th2-dependent airway inflammation and airway hyperresponsiveness. Int. Immunol. 19:755-762 (2007).
  • Kimura, M.Y., Hosokawa, H., Yamashita, M., Hasegawa, A., Iwamura, C., Watarai, H., Taniguchi, M., Takagi, T., Ishii, S. and *Nakayama, T.: Regulation of Th2 cell differentiation by murine Schnurri-2. J. Exp. Med. 201:397-408 (2005).
  • Kimura, M., Koseki, Y., Yamashita, M., Watanabe, N., Shimizu, C., Katsumoto, T., Taniguchi M., Koseki, H. and *Nakayama, T.: Regulation of Th2 cell differentiation by mel-18, a mammalian polycomb group gene. Immunity. 15:275-287 (2001).
  • Kimura, M., Yamashita, M., Kubo, M., Iwashima, M., Shimizu, C., Chiba, J., Taniguchi, M., Katsumata, M. and *Nakayama, T.: Impaired Ca/calcineurin pathway in in vivo anergized CD4 T cells. Int. Immunol. 12:817-824 (2000).

２０２５年

  • Kadariswantiningsih, I.N., Okunaga, I., Yamasaki, K., Empitu, M. A., Yamada, H., Makino, S., Hotta, A., Yagita, H., Aizawa, M., Koyama-Nasu, R., Kimura, M.Y., Tatsumoto, N., Asanuma, K.: CCL5 paradoxically regulates glomerular injury by skewing macrophage polarization. JCI Insight. e173742 (2025).
  • Ozaki , K., Aoki, T., Kobayashi, M., Takami, M., Kobayashi , M., Ito, T., Ogawa, K., Tanaka, H., Nishii, K., Nishimura, K., Motoyoshi, K., Kojima, I., Katsumi, D., Shimizu, D., Wang, H., Kimura, M. Y., Hirahara, K., Koseki, H., Higuchi, Y., Motohashi, S.: Anti-tumor effect of intratumoral administration of induced pluripotent stem cell-derived NKT cells on glioblastoma through CD155/DNAM-1 interaction. Stem Cells Transl Med. 14(9): szaf036 (2025).
  • Endo, Y., Hasegawa, I., Igi, A., Onodera, A., Mita, S., Higashi, K., Kurokawa, K., Toyoda, A., Kiuchi, M., Shinzawa, M., Wang, Y., Koyama-Nasu, R., Hirahara, K., Motohashi, S., Nakayama, T., Kimura, M.Y.: SLAMF6 regulates basal T cell receptor signaling and influences invariant natural killer T cell lineage diversity. Int. Immunol. dxaf030 (2025).
  • Koyama-Nasu, R., Wang, Y., Miyano, H., Kimura, M. Y.: Differentiation of Cytotoxic CD8+ T Cell Subsets Under Tumor Progression: Can CD69 Be a New Therapeutic Target? Cancer Science. 0:1–8 (2025).

２０２４年

  • Aoki, A., Iwamura, C., Kiuchi, M., Tsuji, K., Sasaki, A., Hishiya, T., Hirasawa, R., Kokubo, K., Kuriyama, Sachiko., Onodera, A., Shimada, T., Nagaoka, T., Ishikawa, S., Kojima, A., Mito, H., Hase, R., Kasahara, Y., Kuriyama, N., Nakamura, S., Urushibara, T., Kaneda, S., Sakao, S., Nishida, O., Takahashi, K., Kimura, M.Y., Motohashi, S., Igari, H., Ikehara, Y., Nakajima, H., Suzuki, T., Hanaoka, H., Nakada, T., Kikuchi, T., Nakayama, T., Yokote, K, Hirahara, K.: Suppression of Type I Interferon Signaling in Myeloid Cells by Autoantibodies in Severe COVID-19 Patients. J Clin Immunol. 44(4):104 (2024).
  • Ahmad, I., Omura, S., Sato, F., Park, A.M., Khadka, S., Gavins F.N.E., Tanaka, H., Kimura, M.Y., Tsunoda, I.: Exploring the Role of Platelets in Virus-Induced Inflammatory Demyelinating Disease and Myocarditis. Int. J. Mol. Sci. 25(6): 3460 (2024).

２０２３年

  • Kanno, T., Miyako, K., Endo. T., Yokoyama. S., Asou, H.K., Yamada, K., Ohara, O., Nakayama, T., Kimura, M.Y., Endo, Y.: ACC1-mediated fatty acid biosynthesis intrinsically controls thymic iNKT cell development. Int Immunol. dxad049 (2023).
  • Onodera, A., Kokubo. K., Okano, M., Onoue, M. Kiuchi, M., Iwamura, C.,Iinuma, T., Kimura,M.Y., Ebihara, N., Hanazawa, T., Nakayama, T., Hirahara, K.: Pathogenic helper T cells as the novel therapeutic targets for immune-mediated intractable diseases. Pharmacol Ther. 247:108445 (2023).
  • Koyama-Nasu, R., Kimura, M.Y., Kiuchi, M., Aoki, A., Wang, Y., Mita, Y., Hasegawa, I., Endo, Y., Onodera, A., Hirahara, K., Motohashi, S., Nakayama, T.: CD69 imposes tumor-specific CD8+ T cell fate in tumor-draining lymph nodes. Cancer Immunol. Res. 11(8):1085-1099(2023).
  • Kobayashi, H., Kimura, M.Y., Hasegawa, I., Suganuma, E., Ikehara, Y., Azuma, K., Ito, T., Ebata, R., Kurashima, Y., Kawasaki, Y., Shiko, Y., Saito, N., Iwase, H., Lee, Y., Noval Rivas, M., Arditi, M., Zuka, M., Hamada, H.*, and Nakayama, T.: Increased Myosin light chain 9 expression during Kawasaki disease vasculitis. Front. Immunol. 13:1036672(2023).

２０２２年

  • Koyama-Nasu, R., Wang, Y., Hasegawa, I., Endo, Y., Nakayama, T. and Kimura, M. Y.: The cellular and molecular basis of CD69 function in anti-tumor immunity. Int. Immunol.: dxac024(2022).

２０２１年

  • Nakayama T, Hirahara K, Kimura MY, Iwamura C, Kiuchi M, Kokubo K, Onodera A, Hashimoto K, Motohashi S.: CD4+ T cells in inflammatory diseases: pathogenic T- helper cells and the CD69–Myl9 system. Int. Immunol. 33(12):699-704(2021).
  • Sarkar MH, Yagi R, Endo Y, Koyama-Nasu R, Wang Y, Hasegawa I, Ito T, Junttila IS, Zhu J, Kimura MY, Nakayama T.：IFNγ suppresses the expression of GFI1 and thereby inhibits Th2 cell proliferation. PLoS ONE 16(11): e0260204(2021).
  • Yokoyama, M., Kimura, M.Y., Ito, T., Hayashizaki, K., Endo, Y., Wang, Y., Yagi, R., Nakagawa, T., Kato, N., Matsubara, H. and Nakayama, T.: Myosin light chain 9/12 regulates the pathogenesis of inflammatory bowel disease. Front. Immunol. 11: 594297(2021). 

２０２０年

  • Suzuki, A.S., Yagi, R., Kimura, M.Y., Iwamura, C., Shinoda, K., Onodera, A., Hirahara, K., Tumes, D.J., Koyama-Nasu, R., Lismaa, S.E., Graham, R.M., Motohashi, S. and Nakayama, T.: Essential role for CD30-Transglutaminase 2 axis in memory Th1 and Th17 cell generation. Front. Immunol. 11:1536(2020).
  • Aoki, T., Takami, M., Takatani, T., Motoyoshi, K., Ishii, A., Hara, A., Toyoda, T., Okada, R., Hino, M., Koyama-Nasu, R., Kiuchi, M., Hirahara, K., Kimura, M.Y., Nakayama, T., Shimojo, N., and Motohashi, S.: Activated invariant natural killer T cells directly recognize leukemia cells in a CD1d-independent manner. Cancer Sci. 111(7):2223-2233(2020).
  • Angelou, C.C., Wells, A.C., Vijayaraghavan, J., Dougan, C.E., Lawlor, R., Iverson, E., Lazarevic, V., Kimura, M.Y., Peyton, S.R., Minter, L.M., Osborne, B.A., Pobezinskaya, E.L., *Pobezinsky, L.A.: Differentiation of Pathogenic Th17 Cells is Negatively Regulated by Let-7 MicroRNAs in a Mouse Model of Multiple Sclerosis. Front. Immunol. 17;10:3125(2020).

〜２０１９年

  • Tumes, D., Hirahara, K., Papadopoulos, M., Shinoda, K., Onodera, A., Kumagai, J., Ho Yip, K., Pant, H., Kokubo, K., Kiuchi, M., Aoki, A., Obata-Ninomiya, K., Tokoyoda, K., Endo, Y., Kimura, M.Y. and *Nakayama, T.: Ezh2 controls development of natural killer T cells that cause spontaneous asthma-like pathology. J. Allergy Clin. Immunol.144(2):549-560.e10(2019).
  • Pobezinskaya, E.L., Wells, A.C., Angelou, C.C., Fagerberg, E., Aral, E., Iverson, E., Kimura, M.Y. and Pobezinsky, L.A.: Survival of naïve T cells requires the expression of let-7 miRNAs. Front. Immunol. 3;10:955(2019).
  • Kimura, M.Y., Koyama-Nasu, R., Yagi, R. and Nakayama, T.: A new therapeutic target: the CD69-Myl9 system in immune responses. Semin. Immunopathol. 41(3):349-358(2019).
  • Mita, Y., Kimura, M.Y., Hayashizaki, K., Koyama-Nasu, R., Ito, T., Motohashi, S., Okamoto, Y. and Nakayama, T.: Crucial role of CD69 in anti-tumor immunity through regulating the exhaustion of tumor-infiltrating T cells. Int. Immunol. dxy050(2018).
  • Kimura, M.Y., Igi, A., Hayashizaki, K., Mita, Y., Shinzawa, M., Kadakia, T., Endo, Y., Ogawa, S., Yagi, R., Motohashi, S., Singer, A., and Nakayama, T.: CD69 prevents PLZFhi innate precursors from prematurely exiting the thymus and aborting NKT2 cell differentiation. Nat. Commun. 9: 3749(2018).
  • Kimura, M.Y., Hayashizaki, K., Tokoyoda, K., Takamura, S., Motohashi, S. and Nakayama, T.: Crucial role for CD69 in allergic inflammatory responses. Immunol. Rev. 278:87-100(2017).
  • Hayashizaki, K., Kimura, M.Y., Tokoyoda. K., Hosokawa, H., Shinoda, K., Hirahara, K., Ichikawa, T., Onodera, A., Hanazawa, A., Iwamura, C., Kakuta, J., Muramoto, K., Motohashi, S., Tumes, D.J., Iinuma, T., Yamamoto, H., Ikehara, Y., Okamoto, Y. and Nakayama, T.: Myosin light chain 9 and 12 are functional ligands for CD69 that regulate airway inflammation. Sci Immunol. 1:eaaf9154(2016).
  • Kimura, M.Y., Thomas, J., Tai, X., Cuinter, T.I., Shinzawa, M., Etzensperger, R., Li, Z., Love, P., Nakayama, T. and Singer, A.: Timing and duration of MHC I positive selection signals are adjusted in the thymus to prevent lineage errors. Nat. Immunol, 17:1415-23(2016).
  • Luckey M., Kimura M.Y., Waickman AT., Feigenbaum L., Singer A and Park JH.: The transcription factor ThPOK suppresses Runx3 and imposes CD4 lineage fate by inducing Suppressors Of Cytokine Signaling, Nat. Immunol, 15(7):638-45(2014).
  • Kimura, M.Y., Pobezinsky, L.A., Guinter, T.I., Thomas, J., Adams, A., Park, J.H., Tai, X. and Singer, A.; IL-7 signaling must be intermittent, not continuous, during CD8+ T cell homeostasis to promote cell survival instead of cell death. Nat. Immunol. 14:143-151(2013).